Form 8-K CASI Pharmaceuticals, For: Aug 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CASI Pharmaceuticals (CASI) PT Raised to $6 at Oppenheimer
August 13, 2021 9:21 AM EDTOppenheimer analyst Leland Gershell raised the price target on CASI Pharmaceuticals (NASDAQ: CASI) to $6.00 (from $5.00) while maintaining an Outperform rating.
The analyst commented, "CASI reported another quarter of solid Evomela growth, posting 2Q21 revenue of $7.1M (+25% Q/Q, +173% Y/Y) vs. our $6.2M... More
